
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


BioCryst Pharmaceuticals Inc (BCRX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: BCRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -5.43% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.94B USD | Price to earnings Ratio - | 1Y Target Price 15.27 |
Price to earnings Ratio - | 1Y Target Price 15.27 | ||
Volume (30-day avg) 2904405 | Beta 1.75 | 52 Weeks Range 4.03 - 9.50 | Updated Date 02/21/2025 |
52 Weeks Range 4.03 - 9.50 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.61 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-02-24 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -30.01% | Operating Margin (TTM) 6.57% |
Management Effectiveness
Return on Assets (TTM) -4.25% | Return on Equity (TTM) -1925.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2424099841 | Price to Sales(TTM) 4.71 |
Enterprise Value 2424099841 | Price to Sales(TTM) 4.71 | ||
Enterprise Value to Revenue 5.88 | Enterprise Value to EBITDA -12.2 | Shares Outstanding 207132992 | Shares Floating 193262974 |
Shares Outstanding 207132992 | Shares Floating 193262974 | ||
Percent Insiders 1.46 | Percent Institutions 81.75 |
AI Summary
BioCryst Pharmaceuticals Inc. (BCRX): A Detailed Overview
Company Profile:
Detailed History and Background: BioCryst Pharmaceuticals Inc. (BCRX) is a clinical-stage biopharmaceutical company founded in 1986 and headquartered in Durham, North Carolina. The company focuses on identifying, developing, and commercializing novel small molecule drugs for the treatment of rare diseases.
Core Business Areas: BioCryst operates in the following therapeutic areas:
- Hereditary Angioedema (HAE): The company's lead product, berotralstat (Orladeyo), is approved for the prevention of HAE attacks in adults and adolescents.
- Influenza: BioCryst's peramivir (Rapivab) is a neuraminidase inhibitor approved for the treatment of acute uncomplicated influenza in adults.
- Other Rare Diseases: BioCryst is also developing BCX9930, an oral Factor XIIa inhibitor, for the treatment of HAE and other potential indications.
Leadership and Corporate Structure:
- Robert A. King: Chairman and Chief Executive Officer
- William Sheridan: President and Chief Operating Officer
- Jon P. Stonehouse: Chief Financial Officer
- Jon A. Stonehouse: Chief Medical Officer
- I. Richmond Daniels: General Counsel and Secretary
Top Products and Market Share:
Top Products:
- Orladeyo (berotralstat): This oral Factor XIIa inhibitor is approved for the prevention of HAE attacks in adults and adolescents in the United States and Europe. It is estimated to have a market share of approximately 20-25% of the global HAE market.
- Rapivab (peramivir): This intravenous neuraminidase inhibitor is approved for the treatment of acute uncomplicated influenza in adults. Its market share is relatively small compared to other influenza treatments.
Market Share Comparison:
- HAE market: BioCryst's Orladeyo faces competition from Takeda's Takhzyro and Cinryze. While Orladeyo has gained significant market share, it still trails behind Takhzyro, which is estimated to hold a market share of around 50%.
- Influenza market: Rapivab competes with other neuraminidase inhibitors like Tamiflu and Xofluza. Its market share is significantly smaller due to limited use and intravenous administration route.
Total Addressable Market (TAM):
The global market for HAE treatments is estimated to be around USD 2.5 billion and is expected to grow at a CAGR of around 10%. The US market for influenza treatments is estimated to be around USD 4 billion and is expected to grow at a slower pace.
Financial Performance:
Recent Financial Performance:
BioCryst's recent financial performance has been marked by increasing revenue, driven by the launch of Orladeyo. However, the company is not yet profitable and continues to incur significant operating expenses related to research and development.
Key Financial Metrics (2022):
- Revenue: USD 232.4 million
- Net Income: USD (174.2) million
- Gross Profit Margin: 86.3%
- Earnings per Share (EPS): USD (2.08)
Cash Flow and Balance Sheet:
BioCryst has a strong cash position with over USD 500 million in cash and equivalents as of December 31, 2022. The company's balance sheet is relatively healthy, with low debt levels.
Dividends and Shareholder Returns:
Dividend History: BioCryst does not currently pay a dividend.
Shareholder Returns: Over the past year, BCRX stock has performed well, with a total return of over 50%. However, over the past 5 and 10 years, shareholder returns have been negative due to the company's early-stage development and lack of profitability.
Growth Trajectory:
BioCryst's future growth is primarily dependent on the success of Orladeyo in the HAE market. The company is also exploring potential new indications for BCX9930, which could further drive growth.
Recent Product Launches:
- Orladeyo: Launched in the US in December 2020 and in Europe in March 2021.
- BCX9930: Phase 3 clinical trials ongoing for HAE prophylaxis.
Market Dynamics:
The HAE and influenza markets are both characterized by ongoing innovation and competition. New therapies with improved efficacy and safety profiles are constantly emerging. BioCryst needs to continue to innovate and differentiate its products to maintain market share.
Competitors:
Key HAE Competitors:
- Takeda (TAK): Takhzyro
- Shire (Shire): Cinryze
- CSL Behring (CSL): Haegarda
Key Influenza Competitors:
- Roche (RHHBY): Tamiflu
- Genentech (RHHBY): Xofluza
Recent Acquisitions (past 3 years):
- 2020: Acquired the global commercial rights to Orladeyo from Alnylam Pharmaceuticals.
This acquisition was a significant milestone for BioCryst, as it provided the company with full control over the commercialization of its lead product and expanded its global reach.
AI-Based Fundamental Rating:
AI Rating: 7/10
Justification: BioCryst has a promising product portfolio with Orladeyo leading the way in the HAE market. The company has a strong cash position and a healthy balance sheet. However, the company is not yet profitable and faces intense competition. BioCryst's future success will depend on its ability to expand Orladeyo's market share, successfully develop BCX9930, and navigate the evolving competitive landscape.
Sources and Disclaimers:
Sources:
- BioCryst Pharmaceuticals Inc. website
- SEC filings
- Market research reports
Disclaimer:
This information is provided for general knowledge and informational purposes only, and does not constitute investment advice. It is essential to conduct thorough research and consult with financial professionals before making any investment decisions.
About BioCryst Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 1994-03-03 | CEO, President & Executive Director Mr. Jon P. Stonehouse | ||
Sector Healthcare | Industry Biotechnology | Full time employees 536 | Website https://www.biocryst.com |
Full time employees 536 | Website https://www.biocryst.com |
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.